Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank86
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P86
Within normal range
vs 2Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q3 202522.10%
Q2 202534.91%
Q1 2025-159.60%
Q4 202418.65%
Q3 2024-43.94%
Q2 202416.73%
Q1 2024-164.44%
Q4 2023-10.62%
Q3 202321.07%
Q2 202343.71%
Q1 2023-386.81%
Q4 20220.00%
Q3 20220.00%
Q2 20220.00%
Q1 20220.00%